APOA1 and nasopharyngeal carcinoma: Collectively, an early elevation in ApoA‐I was correlated with better outcomes for anti‐PD‐1 therapy in patients with R/M NPC, suggesting that clinicians should consider the early alteration of ApoA‐I as a useful marker in treating R/M NPC patients with anti‐PD‐1.